Journal article icon

Journal article

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial

Abstract:
We have previously reported on the results of the United Kingdom National Cancer Research Institute (NCRI) AML17 trial, which, for acute promyelocytic leukemia (APL) of all risk groups, compared anthracycline + all-trans retinoic acid (ATRA) (AIDA) vs arsenic trioxide (ATO) + ATRA using an attenuated schedule of ATO.1 Here, we present long-term survival results for randomized patients and for 32 patients who received the same schedule of ATO + ATRA after relapsing from the AIDA arm.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1182/blood-2018-05-851824

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Nuffield Dept of Population Health
Sub department:
Clinical Trial Service Unit
Department:
Unknown
Role:
Author
Publisher:
American Society for Haematology
Journal:
Blood More from this journal
Volume:
132
Issue:
13
Pages:
1452-1454
Publication date:
2018-09-27
Acceptance date:
2018-08-10
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
Keywords:
Pubs id:
pubs:923808
UUID:
uuid:69df1d52-d228-4233-a420-07cb0c00833a
Local pid:
pubs:923808
Source identifiers:
923808
Deposit date:
2018-10-22

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP